Liquidia Corporation to Present at Upcoming Investor Conferences
Liquidia Corporation (NASDAQ: LQDA), a leading biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases, has announced its participation in several key investor conferences this September. These events offer a valuable opportunity for Liquidia to highlight its cutting-edge products and share its strategic vision with investors and industry professionals.
Upcoming Investor Conference Schedule
Liquidia Corporation will be featured at two prominent investor conferences:
Wells Fargo Healthcare Conference
The first event is the 2024 Wells Fargo Healthcare Conference, taking place in Boston. Liquidia is set to present on Thursday, September 5, 2024, from 11:00 to 11:35 a.m. ET. This conference is well-regarded for gathering leading healthcare companies and investors, creating a platform for networking and strategic discussions.
Cantor Global Healthcare Conference
Following that, Liquidia Corporation will participate in the 2024 Cantor Global Healthcare Conference in New York, where the company is scheduled to present on Thursday, September 19, 2024, from 1:30 to 1:50 p.m. ET. This conference serves as an essential venue for biopharmaceutical companies to share their latest developments and operational objectives with both potential and existing investors.
Accessing the Presentations
Investors and interested individuals will have the chance to view the webcasts of these presentations by visiting the official Liquidia Corporation website. Additionally, an archived version of each presentation will be available for at least 30 days after the event, allowing stakeholders to review the content at their convenience.
About Liquidia Corporation
Liquidia Corporation is dedicated to advancing therapies for patients suffering from rare cardiopulmonary diseases. The company is involved in the development and commercialization of innovative products in areas such as pulmonary hypertension. Their proprietary PRINT Technology has played a crucial role in creating their lead product candidate, YUTREPIA™ (treprostinil) inhalation powder. This investigational drug targets pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Moreover, Liquidia is making progress with L606, a sustained-release formulation of treprostinil that is administered twice daily through a next-generation nebulizer. The company also offers a generic version of Treprostinil Injection specifically for treating PAH. Liquidia's ongoing development projects and innovative technology reinforce its position as a leader in the biopharmaceutical industry focused on pulmonary health.
Contact Information
Investors:
Jason Adair
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
919.328.4383
patrick.wallace@liquidia.com
Frequently Asked Questions
What is Liquidia Corporation known for?
Liquidia Corporation is recognized for developing innovative therapies aimed at treating rare cardiopulmonary diseases.
When will Liquidia present at investor conferences?
Liquidia will present at the Wells Fargo Healthcare Conference on September 5, 2024, and at the Cantor Global Healthcare Conference on September 19, 2024.
How can investors access the presentations?
Investors can access the webcasts of the presentations on Liquidia's official website, where archived versions will also be available for at least 30 days after each event.
What products are Liquidia developing?
Liquidia is developing YUTREPIA™ for PAH and L606, a sustained-release formulation of treprostinil, and also markets a generic version of Treprostinil Injection.
Who should be contacted for investor inquiries?
For investor inquiries, Jason Adair is the primary contact at 919.328.4350 or via email at jason.adair@liquidia.com.